Impact of Critical Chain on Drug Development at Eli Lilly
It is rare to get portfolio level data on the impact of Critical Chain. Steven Paul, PhD, President of Lilly Reseach Laboratories, outlines in an Interview with PharmExec the three pillars of Lilly’s business strategy. The first one is the global of adoption of Critical Chain on all Lilly’s R&D projects. He says, ”One hundred percent of the projects using critical chain methodology are on track, either at or ahead of their milestones, as compared to about 60 percent of our traditional development projects.” He also mentioned that Lilly is planning to have all projects under Critical Chain by the end of 2009. Lilly had presented early results of their Critical Chain rollout in two presentations at ProChain’s 9th annual user conference back in 2008.
Here you can find the entire interview.
If you would like to read up on this, then you might find these links helpful. Enjoy!
Indiana Economic Digest on Lilly’s new stragey
BioPharma Today on Lilly’s new strategy
The Point on Critical Chain in the Life Science Industry
The Point on the recent wave of mergers in pharma
- On October 8, 2009